1. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient

   • Zhe Yang
   • Jinqi Yang
   • Xing Wang

   Therapy in Practice 13 July 2019 Pages: 369 - 374

   

2. The Role of Checkpoint Inhibitors in Glioblastoma

   • Kunal Desai
   • Anne Hubben
   • Manmeet Ahluwalia

   Review Article 09 July 2019 Pages: 375 - 394

3. Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis

   • Jisun Park
   • Jinhyun Cho
   • Jinchul Kim

   Systematic Review 09 July 2019 Pages: 395 - 403

   

4. Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data

   • Michael Moran
   • Dana Nickens
   • Kate Fife

   Systematic Review Open access 12 July 2019 Pages: 405 - 416

   

5. Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up

   • Anna W. Chalmers
   • Shiven Patel
   • Wallace Akerley

   Original Research Article 25 July 2019 Pages: 417 - 421

6. Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma

   • Changhui Li
   • Bo Zhang
   • Xueyan Zhang

   Original Research Article 03 July 2019 Pages: 423 - 431

   

7. Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib

   • Chih-Hsi Scott Kuo
   • Chi-Hsien Huang
   • Cheng-Ta Yang

   Original Research Article 25 July 2019 Pages: 433 - 440

   

8. Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane

   • Annelieke E. C. A. B. Willemsen
   • Jolien Tol
   • Carla M. L. van Herpen

   Original Research Article Open access 19 July 2019 Pages: 441 - 451

   

9. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma

   • Hiroki Ishihara
   • Hidekazu Tachibana
   • Kazunari Tanabe

   Original Research Article 29 July 2019 Pages: 453 - 463

   

10. Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer

    • Y. Louise Wan
    • Puja Sapra
    • Peter L. Stern

    Original Research Article Open access 22 July 2019 Pages: 465 - 477

    

11. A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma

    • Fares Nigim
    • Juri Kiyokawa
    • Hiroaki Wakimoto

    Original Research Article 12 July 2019 Pages: 479 - 489

    

12. Correction to: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR‑Mutant Lung Adenocarcinoma

    • Changhui Li
    • Bo Zhang
    • Xueyan Zhang

    Correction 17 July 2019 Pages: 491 - 491